GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axonics Inc (NAS:AXNX) » Definitions » Interest Coverage

Axonics (Axonics) Interest Coverage : 0 (At Loss) (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Axonics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Axonics's Operating Income for the three months ended in Mar. 2024 was $-15.4 Mil. Axonics's Interest Expense for the three months ended in Mar. 2024 was $-0.1 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Axonics's Interest Coverage or its related term are showing as below:


AXNX's Interest Coverage is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 18.37
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Axonics Interest Coverage Historical Data

The historical data trend for Axonics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Axonics Interest Coverage Chart

Axonics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial - - - - N/A

Axonics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A - 30.64 -

Competitive Comparison of Axonics's Interest Coverage

For the Medical Devices subindustry, Axonics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axonics's Interest Coverage Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Axonics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Axonics's Interest Coverage falls into.



Axonics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Axonics's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Axonics's Interest Expense was $0.0 Mil. Its Operating Income was $-4.7 Mil. And its Long-Term Debt & Capital Lease Obligation was $25.8 Mil.

GuruFocus does not calculate Axonics's interest coverage with the available data.

Axonics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, Axonics's Interest Expense was $-0.1 Mil. Its Operating Income was $-15.4 Mil. And its Long-Term Debt & Capital Lease Obligation was $30.2 Mil.

Axonics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Axonics  (NAS:AXNX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Axonics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Axonics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Axonics (Axonics) Business Description

Traded in Other Exchanges
Address
26 Technology Drive, Irvine, CA, USA, 92618
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.
Executives
Karen Noblett officer: Chief Medical Officer 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Kari Leigh Keese officer: Chief Financial Officer 15205 LAFAYETTE WAY, TUSTIN CA 92782
Danny L. Dearen officer: See Remarks 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Ford Alfred J Jr officer: Chief Commercial Officer 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Rinda Sama officer: Chief Operating Officer 26 TECHNOLOGY DRIVE, IRVINE CA 92618
John Woock officer: Chief Marketing Officer 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Raymond W Cohen director, officer: Chief Executive Officer
Esteban Lopez director 6303 COWBOYS WAY, SUITE 600, FRISCO TX 75034
Jane E Kiernan director 525 W ROSCOE, CHICAGO IL 60657
Robert Mcnamara director C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750
David M Demski director C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Robert E Mcnamara director C/O NORTHSTAR NEUROSCIENCE, INC., 2401 FOURTH AVENUE, SUITE 300, SEATTLE WA 98121
Bakker Juliet Tammenoms director, 10 percent owner LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Partners Andera 10 percent owner 374 RUE SAINT ST HONORE, PARIS I0 75001
Raphael Wisniewski director, 10 percent owner 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920